Top

Published in:

Open Access 01-12-2017 | Review

Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder

Authors: Oleg A. Levada, Alexandra S. Troyan

Published in: Annals of General Psychiatry | Issue 1/2017

Abstract

Depression and cognitive dysfunction share a common neuropathological platform. Abnormal neural plasticity in the frontolimbic circuits has been linked to changes in the expression of neurotrophic factors, including IGF-1. These changes may result in clinical abnormalities observed over the course of major depressive disorder (MDD), including cognitive dysfunction. The present review aimed to summarize evidence regarding abnormalities of peripheral IGF-1 in MDD patients and assess a marker and predictive role of the neurotrophin for emotional and cognitive disturbances, and treatment effectiveness. A literature search of the PubMed database was conducted for studies, in which peripheral IGF-1 levels were evaluated. Our analysis revealed four main findings: (1) IGF-1 levels in MDD patients mismatch across the studies, which may arise from various factors, e.g., age, gender, the course of the disease, presence of cognitive impairment, ongoing therapy, or general health conditions; (2) the initial peripheral IGF-1 levels may predict the occurrence of depression in future; (3) peripheral IGF-1 levels may reflect cognitive dysfunction, although the data is limited; (4) it is difficult to evaluate the influence of treatment on IGF-1 levels as there is discrepancy of this growth factor among the studies at baseline, although most of them showed a decrease in IGF-1 levels after treatment.

Kessler RS, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–105.CrossRefPubMed

Vandeleur CL, Fassassi S, Castelao E, Glaus J, Strippoli MF, Lasserre AM, et al. Prevalence and correlates of DSM-5 major depressive and related disorders in the community. Psychiatry Res. 2017;250:50–8.CrossRefPubMed

McIntyre RS, Xiao HX, Syeda K, Vinberg M, Carvalho AF, Mansur RB, et al. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs. 2015;29:577–89.CrossRefPubMed

Baune BT, Miller R, McAfoose J, Johnson M, Quirk F, Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176:183–9.CrossRefPubMed

Lam RW, Kennedy SH, Mclntyre RS, Khullar A. Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. Can J Psychiatry. 2014;59:649–54.CrossRefPubMedPubMedCentral

Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord. 2012;140:113–24.CrossRefPubMed

Bora E, Harrison BJ, Yücel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med. 2013;43:2017–26.CrossRefPubMed

Bortolato B, Carvalho AF, McIntyre RS. Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. CNS Neurol Disord Drug Targets. 2014;13:1804–18.CrossRefPubMed

Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44:2029–40.CrossRefPubMed

10.

Papazacharias A, Nardini M. The relationship between depression and cognitive deficits. Psychiatr Danub. 2012;24(Suppl 1):S179–82.PubMed

11.

Kim HK, Nunes PV, Oliveira KC, Young LT, Lafer B. Neuropathological relationship between major depression and dementia: a hypothetical model and review. Prog Neuropsychopharmacol Biol Psychiatry. 2016;67:51–7.CrossRefPubMed

12.

Carvalho AF, Miskowiak KK, Hyphantis TN, Kohler CA, Alves GS, Bortolato B, et al. Cognitive dysfunction in depression–pathophysiology and novel targets. CNS Neurol Disord Drug Targets. 2014;13:1819–35.CrossRefPubMed

13.

Darcet F, Gardier AM, Gaillard R, David DJ, Guilloux JP. Cognitive dysfunction in major depressive disorder. A translational review in animal models of the disease. Pharmaceuticals. 2016;9(1):9.CrossRefPubMedCentral

14.

Li Y, Pehrson AL, Waller JA, Dale E, Sanchez C, Gulinello M. A critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1)’s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression. Front Neurosci. 2015;9:279.PubMedPubMedCentral

15.

Rial D, Lemos C, Pinheiro H, Duarte JM, Gonçalves FQ, Real JI, et al. Depression as a glial-based synaptic dysfunction. Front Cell Neurosci. 2016;9:521.CrossRefPubMedPubMedCentral

16.

Sweatt JD. Neural plasticity and behavior—sixty years of conceptual advances. J Neurochem. 2016;139(Suppl 2):179–99.CrossRefPubMed

17.

Szczęsny E, Slusarczyk J, Głombik K, Budziszewska B, Kubera M, Lasoń W, et al. Possible contribution of IGF-1 to depressive disorder. Pharmacol Rep. 2013;65:1622–31.CrossRefPubMed

18.

Suh HS, Zhao ML, Derico L, Choi N, Lee SC. Insulin-like growth factor 1 and 2 (IGF1, IGF2) expression in human microglia: differential regulation by inflammatory mediators. J Neuroinflamm. 2013;10:37.CrossRef

19.

Duman R. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol Med. 2004;5:11–25.CrossRef

20.

Mitre M, Mariga A, Chao MV. Neurotrophin signalling: novel insights into mechanisms and pathophysiology. Clin Sci. 2017;131:13–23.CrossRefPubMedPubMedCentral

21.

Matheny RW Jr, Nindl BC, Adamo ML. Minireview: mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010;151:865–75.CrossRefPubMedPubMedCentral

22.

Annunziata M, Granata R, Ghigo E. The IGF system. Acta Diabetol. 2011;48:1–9.CrossRefPubMed

23.

Werner H, LeRoith D. Insulin and insulin-like growth factor receptors in the brain: physiological and pathological aspects. Eur Neuropsychopharmacol. 2014;24:1947–53.CrossRefPubMed

24.

Torres-Aleman I. Toward a comprehensive neurobiology of IGF-I. Dev Neurobiol. 2010;70:384–96.PubMed

25.

Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev. 2005;26:916–43.CrossRefPubMed

26.

Basta-Kaim A, Szczesny E, Glombik K, Stachowicz K, Slusarczyk J, Nalepa I, et al. Prenatal stress affects insulin-like growth factor-1 (IGF-1) level and IGF-1 receptor phosphorylation in the brain of adult rats. Eur Neuropsychopharmacol. 2014;24:1546–56.CrossRefPubMed

27.

Trojan E, Głombik K, Ślusarczyk J, Budziszewska B, Kubera M, Roman A, et al. The beneficial impact of antidepressant drugs on prenatal stress-evoked malfunction of the insulin-like growth factor-1 (IGF-1) protein family in the olfactory bulbs of adult rats. Neurotox Res. 2016;29:288–98.CrossRefPubMed

28.

Trejo JL, Llorens-Martín MV, Torres-Alemán I. The effects of exercise on spatial learning and anxiety-like behavior are mediated by an IGF-I-dependent mechanism related to hippocampal neurogenesis. Mol Cell Neurosci. 2008;37:402–11.CrossRefPubMed

29.

Das SK, Barhwal K, Hota SK, Thakur MK, Srivastava RB. Disrupting monotony during social isolation stress prevents early development of anxiety and depression like traits in male rats. BMC Neurosci. 2015;16:2.CrossRefPubMedPubMedCentral

30.

Beck KD, Powell-Braxton L, Widmer H-R, Valverde J, Hefti F. Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron. 1995;14:717–30.CrossRefPubMed

31.

Lichtenwalner RJ, Forbes ME, Bennett SA, Lynch CD, Sonntag WE, Riddle DR. Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-related decline in hippocampal neurogenesis. Neuroscience. 2001;107:603–13.CrossRefPubMed

32.

Crupi R, Cuzzocrea S. Neuroinflammation and Immunity: a new pharmacological target in depression. CNS Neurol Disord Drug Targets. 2016;15:464–76.CrossRefPubMed

33.

Park SE, Dantzer R, Kelley KW, McCusker RH. Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. J Neuroinflamm. 2011;8:12.CrossRef

34.

Puzik A, Rupp J, Tröger B, Göpel W, Herting E, Härtel C. Insulin-like growth factor-I regulates the neonatal immune response in infection and maturation by suppression of IFN-g. Cytokine. 2012;60:369–76.CrossRefPubMed

35.

Bot M, Milaneschi Y, Penninx BW, Drent ML. Plasma insulin-like growth factor I levels are higher in depressive and anxiety disorders, but lower in antidepressant medication users. Psychoneuroendocrinology. 2016;68:148–55.CrossRefPubMed

36.

Rosso G, Zanardini R, Chiodelli DF, Ferrari C, Gennarelli M, Bocchio-Chiavetto L. Serum levels of insulin-like growth factor-1 and obsessive-compulsive disorder: a case–control study. Neuropsychobiology. 2016;74:15–21.CrossRefPubMed

37.

Sharma AN, da Costa e Silva BF, Soares JC, Carvalho AF, Quevedo J. Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: a comprehensive review of human studies. J Affect Disord. 2016;197:9–20.CrossRefPubMedPubMedCentral

38.

Tu KY, Wu MK, Chen YW, Lin PY, Wang HY, Wu CK, et al. Significantly higher peripheral insulin-like growth factor-1 levels in patients with major depressive disorder or bipolar disorder than in healthy controls: a meta-analysis and review under guideline of PRISMA. Medicine. 2016;95:e2411.CrossRefPubMedPubMedCentral

39.

Chigogora S, Zaninotto P, Kivimaki M, Steptoe A, Batty GD. Insulin-like growth factor 1 and risk of depression in older people: the English Longitudinal Study of Ageing. Transl Psychiatry. 2016;6:e898.CrossRefPubMedPubMedCentral

40.

Van Varsseveld NC, Van Bunderen CC, Sohl E, Comijs HC, Penninx BW, Lips P, et al. Serum insulin-like growth factor 1 and late-life depression: a population-based study. Psychoneuroendocrinology. 2015;54:31–40.CrossRefPubMed

41.

Rusch HL, Guardado P, Baxter T, Mysliwiec V, Gill JM. Improved sleep quality is associated with reductions in depression and PTSD arousal symptoms and increases in IGF-1 concentrations. J Clin Sleep Med. 2015;11:615–23.CrossRefPubMedPubMedCentral

42.

Kopczak A, Stalla GK, Uhr M, et al. IGF-I in major depression and antidepressant treatment response. Eur Neuropsychopharmacol. 2015;25:864–72.CrossRefPubMed

43.

Krogh J, Rostrup E, Thomsen C, Elfving B, Videbech P, Nordentoft M. The effect of exercise on hippocampal volume and neurotrophins in patients with major depression—a randomized clinical trial. J Affect Disord. 2014;165:24–30.CrossRefPubMed

44.

Sievers C, Auer MK, Klotsche J, Athanasoulia AP, Schneider HJ, Nauck M, et al. IGF-I levels and depressive disorders: results from the Study of Health in Pomerania (SHIP). Eur Neuropsychopharmacol. 2014;24:890–6.CrossRefPubMed

45.

Lin F, Suhr J, Diebold S, Heffner KL. Associations between depressive symptoms and memory deficits vary as a function of insulin-like growth factor (IGF-1) levels in healthy older adults. Psychoneuroendocrinology. 2014;42:118–23.CrossRefPubMedPubMedCentral

46.

Emeny RT, Bidlingmaier M, Lacruz ME, Linkohr B, Peters A, Reincke M, Ladwig KH. Mind over hormones: sex differences in associations of well-being with IGF-I, IGFBP-3 and physical activity in the KORA-age study. Exp Gerontol. 2014;59:58–64.CrossRefPubMed

47.

Li SX, Liu LJ, Xu LZ, et al. Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment. Psychoneuroendocrinology. 2013;38:2789–99.CrossRefPubMed

48.

Palomino A, Gonzalez-Pinto A, Martinez-Cengotitabengoa M, et al. Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:29–33.CrossRefPubMed

49.

Weber-Hamann B, Blum WF, Kratzsch J, Gilles M, Heuser I, Deuschle M. Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry. 2009;42:23–8.CrossRefPubMed

50.

Rueda Alfaro S, Serra-Prat M, Palomera E, Falcon I, Cadenas I, Boquet X, Puig Domingo M. Hormonal determinants of depression and cognitive function in independently-living elders. Endocrinol Nutr. 2008;55:396–401.CrossRefPubMed

51.

Michelson D, Amsterdam J, Apter J, Fava M, Londborg P, Tamura R, Pagh L. Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology. 2000;25:169–77.CrossRefPubMed

52.

Franz B, Buysse DJ, Cherry CR, Gray NS, Grochocinski VJ, Frank E, et al. Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication. J Psychiatr Res. 1999;33:121–7.CrossRefPubMed

53.

Deuschle M, Blum WF, Strasburger CJ, Schweiger U, Weber B, Körner A, et al. Insulin-like growth factor-I. IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology. 1997;22:493–503.CrossRefPubMed

54.

Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med. 1996;335:1176–81.CrossRefPubMed

55.

Lesch KP, Rupprecht R, Müller U, Pfüller H, Beckmann H. Insulin-like growth factor I in depressed patients and controls. Acta Psychiatr Scand. 1988;78:684–8.CrossRefPubMed

56.

Mitschelen M, Yan H, Farley JA, Warrington JP, Han S, Hereñú CB, et al. Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression. Neuroscience. 2011;185:50–60.CrossRefPubMedPubMedCentral

57.

Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57:555–9.CrossRefPubMed

58.

Bancos I, Algeciras-Schimnich A, Grebe SK, Donato LJ, Nippoldt TB, Erickson D. Evaluation of variables influencing the measurement of insulin-like growth factor-1. Endocr Pract. 2014;20:421–6.CrossRefPubMed

Title: Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder
Authors: Oleg A. Levada
Alexandra S. Troyan
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Annals of General Psychiatry / Issue 1/2017
Electronic ISSN: 1744-859X
DOI: https://doi.org/10.1186/s12991-017-0161-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial

Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records

A multilevel longitudinal study of obsessive compulsive symptoms in adolescence: male gender and emotional stability as protective factors

Mental, neurologic, and substance use (MNS) disorders among street homeless people in Ethiopia

Effect of lamotrigine in the treatment of bipolar depression with psychotic features: a case report